Chimerix(CMRX) - 2024 Q1 - Quarterly Results

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update – Company to Advance Dordaviprone in Provisional Registration Process Following Positive Interaction with Therapeutic Goods Administration (TGA) in Australia – "Patients, caregivers and physicians are in desperate need for novel therapies that offer clinical benefit in H3 K27M-mutant diffuse glioma, and we believe that dordaviprone (ONC201) has the potential to be a major therapeutic advance in the treatment of this diseas ...